Stanozolol, an anabolic steroid with a high anabolic/androgenic ratio, demonstrates therapeutic potential in various dermatological disorders. Here, we examine its clinical applications in hereditary angioedema (HAE), urticaria, Raynaud’s phenomenon, lipodermatosclerosis, cryofibrinogenemia and pityriasis rubra pilaris. The drug’s unique pharmacokinetic profile, including high oral bioavailability and hepatic metabolism, contributes to its efficacy, particularly in HAE management through enhanced C1-INH production. Notable benefits include reduced frequency of HAE attacks, improved digital microcirculation in secondary Raynaud’s phenomenon, and accelerated ulcer healing in lipodermatosclerosis when combined with compression therapy. However, its use requires careful consideration of potential adverse effects, particularly hepatotoxicity, with close monitoring becoming essential.